The authors modeled loss of IKZF1 function in B cell precursor acute lymphoblastic leukemia (BCP-ALL) cell lines and patient-derived xenografts and compared cellular responses to various chemotherapeutic agents used in the treatment of BCP-ALL.
[Haematologica]